https://padsignaling.com/index.....php/ultrasound-pers
It is our supposition that ONL thinning will provide a clear distinction between FTLD-Tau and individuals with biomarker evidence of AD neuropathologic change (ADNC), and this thinning will reflect the severity of FTLD-Tau disease. Enrolled patients predicted to have FTLD-Tau (pFTLD-Tau; n = 21; 33 eyes) and ADNC (pADNC; n = 24; 46 eyes) underwent optical coherence tomography macula imaging, and subsequent disease categorization (pFTLD-Tau vs. pADNC
Like
Comment
Share
